"Notice: this article appears on the PPSG website with the express permission of the copyright holder, who should be consulted for further permission to reproduce." |
Key Words
Latin America, opioid availability, legislation,
regulations, education, costs
The WHO Cancer Pain Relief and Palliative Care Program for Latin America asked Mr. David E. Joranson, Associate Director for Policy Studies, from the WHO Collaborating Center, University of Wisconsin at Madison, to report the patterns of opioid utilization across Latin America. Members of each country were asked to address the issue directly with their Ministries of Health. It was recommended that each member provide their regional regulator with the consumption report prepared by Mr. Joranson, with the Spanish version of the WHO publication Cancer Pain Relief: A Guide on Opioid Availability.2
The Declaration of Florianopolis recommended that multinational companies be encouraged to import new dosage forms, assist in the training of physicians and health professionals, and assist in updating the legislative and regulatory practices in their countries through their international and legal expertise. Also, national companies were encouraged to prepare simple immediate-release preparations with the assistance of clinicians and nongovernmental organizations, and local pharmacists and local hospitals were encouraged to prepare simple opioid solutions. The WHO Latin American Program agreed to monitor the costs of opioid preparations.
During the 1996 Santo Domingo meeting, many improvements were recorded that had occurred in the 2 years since the Declaration of Florianopolis. The following summarizes the main points.
The data show that countries such as Argentina, Costa Rica, Mexico, and Dominican Republic had a significant decrease in meperidine (pethidine) consumption along with a significant increase in morphine consumption. (Meperidine, although widely used for postsurgical pain management, is not preferred for chronic cancer pain management, due to toxicity from accumulation of metabolites).4 Although some countries such as Colombia, Chile, and Brazil show an increase in the levels of consumption of morphine, they still have higher consumption levels of meperidine than of morphine. Some countries such as the Bahamas, Barbados, Bolivia, Guatemala, Panama, Peru, and Venezuela show little, if any, consumption of morphine, with only meperidine consumption reported. It is even worse in other countries that do not show any consumption of either morphine or meperidine, such as Honduras, El Salvador, Ecuador, Haiti, Jamaica, and Guatemala.
Some of the following reasons, which were cited as barriers to improving morphine use, were the same as those given in the Declaration of Florianopolis:
Recommendations About Availability. It was recommended that Mr. Joranson continue to coordinate the monitoring of opioid use and consumption trends. He will provide members with the data reported annually by the INCB.
Monitoring Availability. Success will be judged by the following criteria:
Monitoring Costs. Success will be judged by the following criteria:
Recommendations About Education.
Monitoring Education. Success will be judged by the following criteria:
A preliminary analysis of the Colombian law was presented by Mr. Joranson and Liliana De Lima, Fellow in Policy Studies, Pain Research Group, WHO Collaborating Center, Madison, Wisconsin. The legislation analysis, which uses criteria based on international treaties and WHO guidelines, serves to enable members from the different countries to identify positive provisions, as well as barriers, within the laws, and the regulations that interfere with the medical use of opioids, and develop recommendations for change.
Recommendations About National Narcotic Legislation.
Monitoring Legislation. Although changes in legislation are slower to achieve, success will be judged by the following criteria:
There appears to be a sharp contrast in the region between countries where opioids are accessible for pain patients and those in which there is almost no access. This contrast does not seem to follow socioeconomic patterns, as can be seen by some wealthier countries in the region having less patterns of utilization than do much poorer countries.
As in the Declaration of Florianopolis, the success of the recommendations made in this report depends on the cooperation of all health professionals, including physicians, nurses, pharmacists, government regulators, pharmaceutical companies, volunteers, political organizations, and health administrators. Regular monitoring will take place to assess the degree of implementation of these recommendations in each country and the success of these recommendations in producing the necessary changes. The results will be discussed again in 1998.
2. World Health Organization Collaborating Center on Symptom
Evaluation, Madison, Wisconsin. Cancer Pain Relief: A Guide to
Opioid Availability. Preprinted with authorization from WHO, 1992.
Alivio del Dolor en el Cancer: Guia sobre la Disponibilidad de Opioides
[Ruiz F. Cepeda S,Jairo M, De Lima, L, Trans]. Printed with previous
authorization from WHO by the Fondo Nacional de Estupefacientes del Ministerio
de Salud de Colombia, Bogota, Colombia, 1994.
3. Joranson DE, Smokowski PR. Opioid Consumption Trends in Latin America: Division of Policy Studies. University of Wisconsin Pain Research Group/WHO Collaborating Center, Madison, Wisconsin, March 1996 (Monograph).
4. Teoh N. Vainio A. The status of pethidine in the WHO model list of essential drugs. Palliat Med 1991;5:185-186.
5. International Narcotics Control Board. Availability of Opiates for Medical and Scientific Needs: Special Report Prepared Pursuant to Economic and Social Council Resolutions 1990/31 and 1991/43. World Health Organization (WHO) Cancer Pain Relief: With a Guide to Availability, 2nd ed. Geneva: WHO, 1996.